CORT stock forecast, quote, news & analysis
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone... Show more
Corcept Therapeutics (CORT) Stock Analysis: Lifyorli Launch and Relacorilant Resubmission Reshape Growth Trajectory
Key Takeaways
- Corcept Therapeutics shares gained approximately 9.2% over the 30-day period ending July 24, 2026, with the stock closing at $95.36, reflecting sustained momentum following multiple pipeline milestones.
- The company secured FDA approval of Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026 — more than three months ahead of its PDUFA date — marking Corcept's transition from a single-product to a multi-product biopharmaceutical company.
- On June 17, 2026, Corcept resubmitted its New Drug Application for relacorilant in Cushing's syndrome, triggering an expected six-month FDA review and renewing investor focus on label expansion for its core endocrinology franchise.
- Full-year 2026 revenue guidance was raised to $950 million–$1.05 billion, while the company reported a Q1 net loss of $31.8 million driven by elevated launch spending for Lifyorli.
- Analysts remain broadly constructive, with price targets ranging from $72 to $135 and a consensus Moderate Buy rating, though the wide target range reflects divergent views on execution and regulatory risk.
Current Market Snapshot
Corcept Therapeutics (CORT) has delivered a notable recovery in 2026 following a turbulent end to 2025, when an FDA Complete Response Letter for relacorilant in Cushing's syndrome triggered a sharp single-day selloff. Since then, the stock has staged a multi-month rally supported by commercial execution, regulatory progress, and pipeline diversification. Over the trailing 30-day window through July 24, 2026, CORT advanced approximately 9.2%, moving from a close of $87.32 on June 26 to $95.36. The shares have also benefited from positive analyst revisions, with several firms lifting price targets following the Lifyorli approval and relacorilant NDA resubmission. Broader biotech sector sentiment and enthusiasm around cortisol modulation as a therapeutic platform have further supported investor interest.
Corcept Therapeutics (CORT) Business Overview and Competitive Position
Corcept Therapeutics is a commercial-stage biopharmaceutical company headquartered in Redwood City, California, focused on discovering and developing medications that modulate the effects of the hormone cortisol. For over 25 years, the company has built a proprietary platform of more than 1,000 selective cortisol modulators and glucocorticoid receptor antagonists. Its first commercial product, Korlym (mifepristone), was approved by the FDA in 2012 for the treatment of endogenous Cushing's syndrome and has been the company's primary revenue driver. In March 2026, Corcept expanded its commercial portfolio with Lifyorli, approved in combination with nab-paclitaxel for adults with platinum-resistant ovarian cancer — the first selective glucocorticoid receptor antagonist cleared for an oncology indication. The company's pipeline also includes dazucorilant for amyotrophic lateral sclerosis (ALS) and miricorilant for metabolic dysfunction-associated steatohepatitis (MASH), along with multiple oncology programs exploring relacorilant combinations across solid tumors.
Recent Developments Driving CORT
Several verified catalysts have shaped Corcept's narrative over the past month. The most consequential was the June 17 resubmission of the relacorilant NDA for Cushing's syndrome, which included additional analyses requested by the FDA and initiated a six-month review clock. This regulatory step is central to Corcept's strategy of reducing its reliance on Korlym, which faces generic competition from Teva Pharmaceuticals following an adverse appellate court decision. The authorized generic version of Korlym now represents roughly 75–78% of volume at an approximately 30% discount to the branded product's wholesale acquisition cost.
Meanwhile, early uptake of Lifyorli in ovarian cancer has been described by management as vigorous, with the NCCN adding the relacorilant-nab-paclitaxel regimen to its guidelines as a preferred option in April 2026. The pivotal ROSELLA trial, published in The Lancet, demonstrated a 35% reduction in risk of death (HR 0.65, p=0.0004). On the analyst front, Canaccord Genuity raised its price target to $135 in late May, while Piper Sandler lifted its target to $88. UBS upgraded the stock to Buy on May 13. The company also reported two-year overall survival data from the Phase 2 DAZALS ALS trial, showing an 87% reduction in mortality risk at the 300 mg dose, and announced plans to initiate a Phase 3 study later in 2026.
Other notable developments include Corcept's removal from the Russell 1000 Defensive Index and Russell 1000 Growth-Defensive Index in late June — a passive-investing event with limited fundamental impact — and the Department of Justice declining to intervene in a long-running qui tam lawsuit related to Korlym promotion. Insider selling under pre-established Rule 10b5-1 plans has been observed, though these transactions were scheduled well in advance and do not signal a change in management sentiment.
Trending AI Robots
For investors seeking data-driven approaches to navigate stocks like Corcept Therapeutics, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered trading robots that actively trade thousands of tickers, but only the most relevant and consistently strong performers appear in this trending section. These bots vary widely in trading strategy, holding period, and performance metrics — from short-term swing trading to longer-duration trend-following models — allowing users to identify approaches aligned with their own risk tolerance and investment horizon. Monitoring which bots are trending can provide a unique perspective on shifting market dynamics and momentum patterns.
2026 Outlook and What Investors Should Watch
The second half of 2026 will be pivotal for Corcept Therapeutics. Investors should monitor the upcoming Q2 2026 earnings report and corporate update for early commercial metrics on Lifyorli, including prescription volumes, payer coverage progress, and revenue contribution from the oncology franchise. The relacorilant Cushing's syndrome NDA review is expected to conclude around December 2026; any additional FDA information requests or an advisory committee meeting could influence sentiment. The BELLA trial combining relacorilant with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer is expected to produce results by year-end, alongside the MONARCH Phase 2b readout for miricorilant in MASH. A Phase 3 ALS trial for dazucorilant is also expected to begin enrolling patients before year-end. On the competitive front, the trajectory of Korlym's authorized generic volume share and pricing pressure will remain a key variable for near-term margins, as will the company's ability to scale its specialty pharmacy network to meet rising demand. With a cash and investments position of $515.4 million as of March 31, 2026, Corcept retains financial flexibility, though rising R&D and SG&A spending tied to commercial launches and pipeline advancement warrant continued attention.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CORT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for CORT turned positive on July 30, 2026. Looking at past instances where CORT's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 23, 2026. You may want to consider a long position or call options on CORT as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CORT advanced for three days, in of 328 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 273 cases where CORT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CORT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CORT broke above its upper Bollinger Band on July 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CORT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.544) is normal, around the industry mean (19.620). CORT has a moderately high P/E Ratio (254.422) as compared to the industry average of (38.277). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.532). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. P/S Ratio (16.260) is also within normal values, averaging (420.906).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drugs for the treatment of severe psychiatric and neurological diseases
Industry Biotechnology